We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
-0.92%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$313M
AUM Growth
+$43.7M
Cap. Flow
+$70.4M
Cap. Flow %
22.5%
Top 10 Hldgs %
58.61%
Holding
92
New
33
Increased
17
Reduced
11
Closed
31

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$26.8M
2
DXCM icon
DexCom
DXCM
+$24.3M
3
ABBV icon
AbbVie
ABBV
+$21.2M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$20.1M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$25.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$21.1M
3
MDT icon
Medtronic
MDT
+$14.2M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.82M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.66M

Sector Composition

Rank Sector Weight
1 Healthcare 92.58%
2 Industrials 0.23%
3 Financials 0.16%
4 Technology 0.14%
5 Energy 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRSN
76
DELISTED
Mersana Therapeutics
MRSN
– –
-17,132
Closed -$1.41M
MRUS
77
DELISTED
Merus
MRUS
– –
-101,691
Closed -$2.68M
PRU icon
78
Prudential Financial
PRU
$41.9B
– –
-2,463
Closed -$217K
PTGX icon
79
Protagonist Therapeutics
PTGX
$9.4B
– –
-33,750
Closed -$932K
RITM icon
80
Rithm Capital
RITM
$5.55B
– –
-13,531
Closed -$127K
ROIV icon
81
Roivant Sciences
ROIV
$25.4B
– –
-202,406
Closed -$2.04M
STVN icon
82
Stevanato
STVN
$5.54B
– –
-176,359
Closed -$5.71M
UA icon
83
Under Armour Class C
UA
$2.67B
– –
-11,603
Closed -$77.9K
VRTX icon
84
Vertex Pharmaceuticals
VRTX
$123B
– –
-24,597
Closed -$8.66M
VTRS icon
85
Viatris
VTRS
$19B
– –
-10,379
Closed -$104K
VTYX
86
DELISTED
Ventyx Biosciences
VTYX
– –
-57,800
Closed -$1.9M
NARI
87
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-113,441
Closed -$6.6M
CERE
88
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-41,292
Closed -$1.31M
CBAY
89
DELISTED
Cymabay Therapeutics
CBAY
– –
-70,588
Closed -$773K
MRTX
90
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-24,201
Closed -$874K
RETA
91
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-96,274
Closed -$9.82M
INBX
92
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-15,268
Closed -$396K
1 2 3
4

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return

Tri Locum Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Tri Locum Partners held 92 positions worth $313M, up 16% from $269M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Tri Locum Partners deployed $70.4M of net new capital in Q3 2023, opening 33 new positions and adding to 17 existing holdings. Its largest new stake was Amgen: 107,480 shares worth $28.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 99% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was West Pharmaceutical, an estimated $7M trimmed.

  • Tri Locum Partners's largest Q3 2023 buy was Amgen: 107,480 shares worth $28.9M.
  • Tri Locum Partners added most to DexCom in Q3 2023, an estimated $24.3M increase.
  • Tri Locum Partners's biggest Q3 2023 reduction was West Pharmaceutical, cutting an estimated $7M.
  • Tri Locum Partners fully exited Eli Lilly in Q3 2023, selling an estimated $25.5M.
  • Tri Locum Partners's ten largest holdings make up 59% of its $313M portfolio in Q3 2023.
  • Tri Locum Partners opened 33 new positions and closed 31 in Q3 2023.
  • Tri Locum Partners's portfolio value rose 16% quarter-over-quarter to $313M.

Based on Tri Locum Partners's 13F filing for Q3 2023, filed 14 Nov 2023.